Thursday, December 14, 2017
As the nation grapples for solutions to the opioid epidemic—now claiming more than 33,000 American lives each year—the potential of the psychoactive plant kratom to become a useful tool in the battle has been hotly debated.
While some in the medical field and many in the general public attest to kratom’s ability to help curb opioid addiction and relieve pain, governmental agencies continue to warn against its dangers to mental health, citing links to psychosis and addiction. In 2016, the DEA briefly recommended criminalizing kratom possession and distribution, before withdrawing the proposal.
But a recently published review of 57 years of international scientific evidence, led by researchers at the University of Rochester Medical Center (URMC) and the University of British Columbia, may help reduce misconceptions about kratom and restore its potential as a public health tool that deserves more research.
The study not only points to the potential benefits of kratom as a safer substitute for opioids, but suggests the plant’s potential to reduce negative mood and relieve anxiety. Published online this week in the journal Drug and Alcohol Dependence, it represents the largest systematic review of the scientific literature on kratom use and mental health.
“There is a lot of confusing information about kratom in the media that makes it difficult for clinicians and the public to make informed choices,” said lead author Marc T. Swogger, Ph.D., associate professor in URMC’s Department of Psychiatry. “This study clarifies that there is no good scientific basis for claims that kratom causes psychosis, suicide, or violence, and the available data do not indicate that kratom is a significant public health problem.”
Co-author Zach Walsh, Ph.D., associate professor of Psychology at the University of British Columbia notes that current approaches to addressing the opioid epidemic are leaving large numbers of high-need individuals without effective treatment.
“We need to explore all options, and our findings suggest it’s time to carefully examine the potential of this ancient plant,” said Walsh.
Swogger and Walsh reviewed the combined results of 13 studies conducted between January 1960 and July 2017, using data from 28,745 individuals. “There is a clear need for more rigorous, well-controlled, prospective studies to support a sophisticated, nuanced understanding of the plant,” said Swogger. “But data across cultures indicated that kratom has a legitimate role to play in mitigating harms associated with opioid dependence. The bulk of the available research supports kratom’s benefits as a milder, less addictive and less-dangerous substance than opioids, and one that appears far less likely to cause fatal overdose
Kratom (Mitragyna speciosa; also known as krathom or ketum) is part of the coffee family and has been used medicinally for centuries in Southeast Asia to relieve symptoms of opioid withdrawal, to relieve pain, diarrhea and cough, and increase stamina and energy. People chew raw leaves of the kratom plant, boil them to serve as tea, smoke or vaporize them. In recent years, kratom’s use has expanded beyond Asia, and its leaves, powders, gums, capsules and extracts are widely accessed through retail outlets and the internet in North America and Europe.
“We need more and better research to be able to outline the risks and benefits of kratom in greater detail,” he said. “Only through well-controlled studies can we elucidate kratom’s potential for good and harm, and give the public, policy makers and health care professionals the information needed to make informed decisions.”
Media Contact: Christine Roth (585) 275-1309